Dangerous Medicines

The Journal of American College of Cardiology published a study from Europe showing an increased rate of gastrointestinal bleeding, dyspepsia (pain in stomach), and a trend toward increased risk of heart attacks for users of the new anti-coagulant drug Pradaxa.  This comes following a presentation made at the American College of Cardiology meeting in March [...]

Judge Tim Fox in Little Rock entered a penalty of 1.2 BILLION dollars after a jury returned a verdict against drug maker Johnson and Johnson on behalf of the State of Arkansas for medicaid fraud. The claim was filed as a result of misrepresentations made by J&J about its drug Risperdal by the Arkansas Attorney [...]

The Federal Drug Administration has announced that as of February 28, 2011 that all statins must carry a warning on their label about the increased risk that they cause for development of diabetes along with memory and cognition problems.  This warning applies across the board to statins which include such name brands as: Lipitor Mevacor [...]

Sean Keith, the partner in our firm handling  the Transvaginal Mesh claims in  our office attended two meetings in Phoenix with  TV Mesh lawyers  from across the  country to discuss the latest news regarding TV Mesh cases.  Recently a federal judicial panel ruled that all federal cases should be transferred to West Virginia to be [...]

The FDA announced today that it is investigating reports of serious bleeding in patients taking the drug Pradaxa. Pradaxa is a blood thinning drug (anti-coagulant) used to reduce the risk of stroke in patients with heart rhythm abnormalities (atrial fibrillation). According to the announcement issued by the agency it stated the “FDA is working to [...]

The U.S. Food and Drug Administration (FDA) is continuing its review of the potential increased risk of blood clots with the use of birth control pills containing drospirenone (found in the drugs Yaz, Yasmine and Yasminella birth control pills) FDA is releasing the final report of the FDA-funded study that evaluated the risk of blood [...]

The FDA has reveiwed the results from two FDA sponsored studies performed to evaluate the risk of neuropsychiatric problems associated with the smoking cessation drug Chatnix. Neither study found a difference in risk of neuropsychiatric hospitalizations between Chantix and nicotine replacement therapy (NRT; e.g., NicoDerm patches). However, both studies had a number of study design [...]